This sentiment might seem appropriate for a Hollywood movie, but it can also be applied to the building of a minimally invasive aortic valve replacement (MIAVR) program. That is to say, if we build it, patients will come. While the goal of this article is not to describe the advantages ...
The breakthrough came with the first TAVI procedure in France in 2002, revolutionizing heart valve replacement through an interventional approach [1]. In recent years, TAVI has gained popularity, particularly suitable for high-risk patients [2]. Transapical TAVI presents several advantages, including...
To date, drug therapies used for lowering cholesterol circulatory levels [9] and renin-angiotensin system inhibitors [10] were ineffective to delay the progression of severe AVS, and thus surgical and transcatheter aortic valve replacement with a mechanical or bioprosthetic valve represents the only av...